Aqumeldi® is an innovative formulation and the first and only paediatric-licensed enalapril ODT for heart failure — because children are not just small adults1-3:
- Aqumeldi® - dedicated paediatric clinical studies in HF establishing its safety profile over a duration of 1 year4,5
- Aqumeldi® is an innovative paediatric formulation — a mini ODT that rapidly disperses in the mouth1,4
- Aqumeldi® is readily available in a low dose strength (0.25 mg) — enabling accurate titration and dose adjustments1,4
Paediatric medication should be in an age-appropriate formulation, accepted by children with convenient administration.
- HCPs, parents and caregivers are often required to manipulate an adult medicine to obtain an appropriate dose for a child6
- Patient acceptability is likely to have a significant impact on patient adherence and consequently on the safety and efficacy of the medicine.5
- The World Health Orgnisation has proposed a shift from liquid administration to small-size solid drug formulation administration for children7
- Mini ODTs have been designed specifically for paediatric patients to aid accurate dose administration, removing the need to manipulate adult formulations1,8,9
Use the links below to explore
-
Dosing & Administration
Head to this section for guidance on the dosing and administration of Aqumeldi®
-
Clinical Evidence
Read more about the LENA trials and clinical data supporting the development and licensing of Aqumeldi® here
-
Resources
Discover resources for patients and healthcare professionals.